evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,549 questions · 1,604 findings · 181 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 258 · 16.1%GRADE not reported 69 · 4.3%Very low 337 · 21%Low 406 · 25.3%Moderate 410 · 25.6%High 124 · 7.7%

Betamethasone acetate plus phosphate vs betamethasone phosphate – fetal/neonatal outcomes

Any known death after randomisation (fetal, neonatal, child, child as adult) · women at risk of preterm birth

It is very uncertain whether betamethasone acetate plus phosphate changes any known death after randomisation (fetal, neonatal, child, child… compared with betamethasone phosphate – fetal/neonatal outcomes (very low certainty).

1 finding from 1 review

Betamethasone acetate plus phosphate vs betamethasone phosphate – fetal/neonatal outcomes

Respiratory distress syndrome · women at risk of preterm birth

It is very uncertain whether betamethasone acetate plus phosphate changes respiratory distress syndrome compared with betamethasone phosphate – fetal/neonatal outcomes (very low certainty).

1 finding from 1 review

Betamethasone acetate plus phosphate vs betamethasone phosphate – fetal/neonatal outcomes

Intraventricular haemorrhage · women at risk of preterm birth

It is very uncertain whether betamethasone acetate plus phosphate changes intraventricular haemorrhage compared with betamethasone phosphate – fetal/neonatal outcomes (very low certainty).

1 finding from 1 review

Betamethasone 12‐hourly vs 24‐hourly dosing – fetal/neonatal outcomes

Any known death after randomisation (fetal, neonatal, child, child as adult) · women at risk of preterm birth

It is very uncertain whether betamethasone 12‐hourly changes any known death after randomisation (fetal, neonatal, child, child… compared with 24‐hourly dosing – fetal/neonatal outcomes (very low certainty).

1 finding from 1 review

Betamethasone 12‐hourly vs 24‐hourly dosing – fetal/neonatal outcomes

Respiratory distress syndrome · women at risk of preterm birth

It is very uncertain whether betamethasone 12‐hourly changes respiratory distress syndrome compared with 24‐hourly dosing – fetal/neonatal outcomes (very low certainty).

1 finding from 1 review

Betamethasone 12‐hourly vs 24‐hourly dosing – fetal/neonatal outcomes

Intraventricular haemorrhage · women at risk of preterm birth

It is very uncertain whether betamethasone 12‐hourly changes intraventricular haemorrhage compared with 24‐hourly dosing – fetal/neonatal outcomes (very low certainty).

1 finding from 1 review

Betamethasone 12‐hourly vs 24‐hourly dosing – fetal/neonatal outcomes

Chronic lung disease · women at risk of preterm birth

It is very uncertain whether betamethasone 12‐hourly changes chronic lung disease compared with 24‐hourly dosing – fetal/neonatal outcomes (very low certainty).

1 finding from 1 review

Betamethasone 12‐hourly vs 24‐hourly dosing – fetal/neonatal outcomes

Necrotising enterocolitis · women at risk of preterm birth

It is very uncertain whether betamethasone 12‐hourly changes necrotising enterocolitis compared with 24‐hourly dosing – fetal/neonatal outcomes (very low certainty).

1 finding from 1 review

Dexamethasone vs betamethasone – maternal outcomes

Maternal adverse effects of therapy · women at risk of preterm birth

Dexamethasone showed no clear difference in maternal adverse effects of therapy compared with betamethasone – maternal outcomes (moderate certainty).

1 finding from 1 review

Dexamethasone vs betamethasone – child outcomes

Any known death after randomisation (fetal, neonatal, child, child as adult) · women at risk of preterm birth

Dexamethasone showed no clear difference in any known death after randomisation (fetal, neonatal, child, child… compared with betamethasone – fetal/neonatal outcomes (moderate certainty).

1 finding from 1 review

Moderate‐potency vs mild‐potency topical corticosteroid

Clinician‐reported signs of eczema: IGA (number with cleared or marked improvement); short term (earliest time within 1‐5 weeks) · children and adults with mild to severe eczema

Moderate‐potency probably leads to higher clinician‐reported signs of eczema: IGA (number with cleared or… compared with mild‐potency topical corticosteroid (moderate certainty).

1 finding from 1 review

Potent vs moderate‐potency topical corticosteroid

Patient‐reported symptoms of eczema · children and adults, most with moderate to severe eczema

Potent may leads to lower patient‐reported symptoms of eczema: PGA; short‐term (week 1) compared with moderate‐potency topical corticosteroid (low certainty).

1 finding from 1 review